By Michael Erman and Christy Santhosh Jan 20 (Reuters) - Novavax said on Tuesday it signed a licensing agreement allowing ...

Earlier in January 2026, Novavax announced a non-exclusive license and option agreement granting Pfizer worldwide rights to ...

Pfizer is paying $30 million to use Novavax’s adjuvant technology to improve the efficacy of two of the Big Pharma’s vaccine ...

Novavax’s Pfizer Matrix-M licensing deal brings $30M upfront, milestones & royalties. Read the full analysis here.

Under the terms of the agreement, Pfizer is expected to pay an upfront total of $30 million in early 2026 to Novavax, while ...

Pfizer will now employ Novavax’s adjuvant, Matrix-M, into its vaccines across two disease areas.

Pfizer CEO Albert Bourla said that the main thing getting in the way of changing vaccine discussions in the U.S. is the ...

Meanwhile, during the WSJ event in Davos this week, Pfizer’s Bourla also took aim at the Trump administration’s moves to cut ...

In today’s ACT Brief, we look at how global clinical development is evolving through decentralized models and emerging ...

An analysis of safety data suggests that Abrysvo, the Pfizer respiratory syncytial virus (RSV) RSVpreF vaccine, does not ...

Maryland-based Novavax signed a licensing agreement allowing Pfizer access to its technology that boosts immune responses to ...

Novavax ‌said on ‌Tuesday it was ⁠entering ‌into a ‍licensing agreement with ​Pfizer ‌to develop vaccine products ⁠for ...